Evaluation of Plasma and Tissue S100A4 Protein and mRNA Levels as Potential Markers of Metastasis and Prognosis in Clear Cell Renal Cell Carcinoma

Abstract

OBJECTIVES: To investigate levels of S100A4 protein in plasma and S100A4 mRNA in tumours from patients with clear cell renal cell carcinoma (CCRCC), and correlate these with metastasis, survival and levels of vascular endothelial growth factor (VEGF). METHODS: Plasma S100A4 and VEGF protein concentrations were measured using enzyme-linked immunosorbent assays in 39 healthy subjects and 68 consecutive patients with untreated CCRCC. Levels of S100A4 and VEGF mRNA in tumour and matched control (healthy) tissue samples were measured using real-time quantitative reverse transcription—polymerase chain reaction. Findings were analysed with respect to clinicopathological characteristics. RESULTS: Plasma VEGF concentrations were higher in patients with CCRCC than in healthy subjects. S100A4 and VEGF mRNA levels were up-regulated in CCRCC tumour tissue compared with control tissue samples. Logistic regression analysis revealed that up-regulated tumour S100A4 and VEGF mRNA levels were independent risk factors for the presence of invasion and/or metastasis. CONCLUSIONS: S100A4 and VEGF are associated with tumour invasion and metastasis, and may be useful prognostic markers in patients with CCRCC. S100A4 and VEGF may represent potential targets for therapeutic intervention.

Keywords

Clear Cell Renal Cell Carcinoma (CCRCC)Metastasis Survival Calcium-Binding Protein S100A4 Vascular Endothelial Growth Factor (VEGF)

References

Kaelin

Jr : New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am 2011; 25: 667–686.

Strohmeyer

Ackermann

: Classic and modern prognostic indicators in renal cell carcinoma. Review of the literature. Urol Int 1991; 47: 203–212.

Nagashima

Inayama

Kato

: Pathological and molecular biological aspects of the renal epithelial neoplasms, up-to-date. Pathol Int 2004; 54: 377–386.

Ayerbes

M Valladares

Gallego

G Aparicio

Prado

S Díaz

: Origin of renal cell carcinomas. Clin Transl Oncol 2008; 10: 697–712.

Garrett

Varney

Weber

: S100A4, a mediator of metastasis. J Biol Chem 2006; 281: 677–680.

Boye

Maelandsmo

: S100A4 and metastasis: A small actor playing many roles. Am J Pathol 2010; 176: 528–535.

Helfman

Kim

Lukanidin

: The metastasis associated protein S100A4: role in tumour progression and metastasis. Br J Cancer 2005; 92: 1955–1958.

Tarabykina

Griffiths

Tulchinsky

: Metastasis-associated protein S100A4: spotlight on its role in cell migration. Curr Cancer Drug Targets 2007; 7: 217–228.

Rosty

: Towards the identification of new markers of pancreatic cancer by gene expression analysis. Bull Cancer 2004; 91: 593–598 [in French, English abstract].

10.

Ferrara

: Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9 (suppl 1): 2–10.

11.

Golshayan

Brick

Choueiri

: Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. Future Oncol 2008; 4: 85–92.

12.

Botelho

Pina

Lunet

: VEGF and prostatic cancer: A systematic review. Eur J Cancer Prev 2010; 19: 385–392.

13.

Moran

Yang

Goyal

: Evaluation of vascular endothelial growth factor as a prognostic marker for local relapse in early-stage breast cancer patients treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 2011; 81: 1236–1243.

14.

George

Bukowski

: Biomarkers in clear cell renal cell carcinoma. Expert Rev Anticancer Ther 2007; 7: 1737–1747.

15.

Nieder

Andratschke

Jeremic

: Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer. Anticancer Res 2003; 23: 5117–5123.

16.

Dorff

Goldkorn

Quinn

: Targeted therapy in renal cancer. Ther Adv Med Oncol 2009; 1: 183–205.

17.

Yang

Haworth

Sherry

: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427–434.

18.

Gordon

: Novel antiangiogenic therapies for renal cell cancer. Clin Cancer Res 2004; 10: 6377S–6381S.

19.

Huang

: Prognostic significance of S100A4 and vascular endothelial growth factor expression in pancreatic cancer. World J Gastroenterol 2008; 14: 1931–1935.

20.

Fleming

: Kidney. In: AJCC Cancer Staging Manual, 5th edn ( Fleming

ed). Philadelphia: Lippincott-Raven, 1997; pp 231–239.

21.

Fuhrman

Lasky

Limas

: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655–663.

22.

Zou

Al-Baradie

Al Hindi

: S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma. Br J Cancer 2005; 93: 1277–1284.

23.

Bièche

Olivi

Champème

: Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. Int J Cancer 1998; 78: 661–666.

24.

Rosivatz

Becker

Specht

: Differential expression of the epithelial—mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 2002; 161: 1881–1891.

25.

Mazzucchelli

: Protein S100A4: too long overlooked by pathologists? Am J Pathol 2002; 160: 7–13.

26.

Marenholz

Lovering

Heizmann

: An update of the S100 NomenClature. Biochim Biophys Acta 2006; 1763: 1282–1283.

27.

Donato

: Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003; 60: 540–551.

28.

Schneider

Hansen

Sheikh

: S100A4: A common mediator of epithelial—mesenchymal transition, fibrosis and regeneration in diseases? J Mol Med (Berl) 2008; 86: 507–522.

29.

Rudland

Platt-Higgins

Renshaw

: Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. Cancer Res 2000; 60: 1595–1603.

30.

de Silva Rudland

Martin

Roshanlall

: Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer. Clin Cancer Res 2006; 12: 1192–1200.

31.

Lee

Lin

: Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer. Oncology 2004; 66: 429–438.

32.

Pedersen

Nesland

Fodstad

: Expression of S100A4, E-cadherin, α- and β-catenin in breast cancer biopsies. Br J Cancer 2002; 87: 1281–1286.

33.

Heizmann

Allard

Birchmeier

: The metastasis-associated gene S100A4 is a novel target of β-catenin/T-cell factor signaling in colon cancer. Gastroenterology 2006; 131: 1486–1500.

34.

Flatmark

Maelandsmo

Mikalsen

: Immunofluorometric assay for the metastasis-related protein S100A4: release of S100A4 from normal blood cells prohibits the use of S100A4 as a tumor marker in plasma and serum. Tumour Biol 2004; 25: 31–40.

35.

Ambartsumian

Klingelhöfer

Grigorian

: The metastasis-associated Mts1 (S100A4) protein could act as an angiogenic factor. Oncogene 2001; 20: 4685–4695.

36.

Rini

: Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 2007; 13: 1098–1106.